NDC 72682-2230
This exact product or package identity exists in FDA auxiliary data but is not present in the current primary NDC product table. The package identity is preserved; status rows are reported source observations, not medical conclusions.
- Requested NDC
- 72682-2230
- Product root
- 72682-2230
- Identity scope
- Product
- Primary current NDC product row
- Not present
NDC auxiliary status#
These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| compounder | package | 72682-2230 | 72682-2230-1 | COMPOUNDER | Outsourcing facility compounded drug report | 2024-1 | 2026-10-21 |
| compounder | package | 72682-2230 | 72682-2230-3 | COMPOUNDER | Outsourcing facility compounded drug report | 2023-1 | 2026-10-21 |
| compounder | package | 72682-2230 | 72682-2230-3 | COMPOUNDER | Outsourcing facility compounded drug report | 2022-2 | 2026-10-21 |
| compounder | package | 72682-2230 | 72682-2230-3 | COMPOUNDER | Outsourcing facility compounded drug report | 2022-1 | 2026-10-21 |
Observed NDC auxiliary status history#
This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
| Captured / source date | Package NDC | Reporting period | Snapshot | Source SHA-256 |
|---|---|---|---|---|
| 2025-12-16 00:49 UTC · source 2025-09-25 | 72682-2230-1 | 2024-1 | 3f6f48d8db7b… | 6316a3eebc6a… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 72682-2230-1 | 2024-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 72682-2230-3 | 2023-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 72682-2230-3 | 2022-2 | af8e9b524e63… | ca326a94a5e9… |
| 2025-08-27 00:00 UTC · source 2025-08-20 | 72682-2230-3 | 2022-1 | af8e9b524e63… | ca326a94a5e9… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 72682-2230-1 | 2024-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 72682-2230-3 | 2023-1 | 85f958c8d153… | 997044a9741e… |
| 2025-01-13 04:20 UTC · source 2024-11-20 | 72682-2230-3 | 2022-2 | 85f958c8d153… | 997044a9741e… |
Compounder NDC reports#
| Establishment | FEI | Product NDC | Package NDC | Product | Active ingredients | Reporting period | Normalization |
|---|---|---|---|---|---|---|---|
| AnazaoHealth Corporation | 796692619 | 72682-2230 | 72682-2230-1 | Riboflavin; Niacinamide; Dexpanthenol; Pyridoxine; Thiamine Hydrochloride | 2 mg/1 mL; 75 mg/1 mL; 6.6 mg/1 mL; 2 mg/1 mL; 75 mg/1 mL | 2024-1 | valid |
| AnazaoHealth Corporation | 796692619 | 72682-2230 | 72682-2230-3 | Riboflavin; Niacinamide; Dexpanthenol; Pyridoxine; Thiamine Hydrochloride | 2 mg/1 mL; 75 mg/1 mL; 6.6 mg/1 mL; 2 mg/1 mL; 75 mg/1 mL | 2023-1 | valid |
| AnazaoHealth Corporation | 796692619 | 72682-2230 | 72682-2230-3 | Riboflavin; Niacinamide; Dexpanthenol; Pyridoxine; Thiamine Hydrochloride | 2 mg/1 mL; 75 mg/1 mL; 6.6 mg/1 mL; 2 mg/1 mL; 75 mg/1 mL | 2022-2 | valid |
| AnazaoHealth Corporation | 796692619 | 72682-2230 | 72682-2230-3 | Riboflavin; Niacinamide; Dexpanthenol; Pyridoxine; Thiamine Hydrochloride | 2 mg/1 mL; 75 mg/1 mL; 6.6 mg/1 mL; 2 mg/1 mL; 75 mg/1 mL | 2022-1 | valid |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.